Table 1 Clinical characteristics of patient samples used.

Mean ± SD is shown. Parentheses indicate percentages. “Other biologics” includes rituximab, tofacitinib, and abatacept. ACPA, anticitrullinated protein antibody; CDAI, clinical disease activity index; CRP, C-reactive protein; NA, not applicable; TNF, tumor necrosis factor.

Mass cytometry cohortFlow cytometry cohort
ControlsCasesControlsCases
Blood cross-sectional
cohorts
Number26262739
Age57 ± 1566 ± 961 ± 1458 ± 14
Female19 (73)20 (77)18 (64)30 (77)
ACPA- or RF-positiveNA22 (85)NA39 (100)
CRP (mg/liter)NA8.6 ± 16.9NA9.8 ± 17.9
CDAINA9.3 ± 4.4NA13.7 ± 7.4
Methotrexate018 (69)018 (46)
Anti-TNF010 (38)016 (41)
Other biologics05 (19)09 (23)
Longitudinal
cohort
Blood longitudinal cohortNumber18
Age49 ± 17
Female17 (94)
ACPA- or RF-positive18 (100)
CDAI before17.6 ± 9.3
CDAI after6.3 ± 4.2
Started methotrexate7
Started anti-TNF4
Started other biologic7
Patient#1#2#3#4#5#6#7#8#9
Synovial tissue donorsAge575476464679626352
SexFFFFFFMMF
CRP (mg/liter)2588111719136676
CDAI1491715212559NA
MethotrexateNoYesNoNoNoNoNoYesNo
Biologic therapyYesYesYesYesYesNoNoNoNo